New unemployment filings in Maryland fell significantly last week, offering a spot of positive news for the state's labor market as national claims also edged lower.
Rights groups document a disturbing pattern of Iranian security forces raiding hospitals to arrest injured protesters and the medical personnel treating them, transforming sanctuaries of care into sites of fear and reprisal.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
Financial Institutions Inc. (FISI) reported solid Q4 and full-year 2025 results, with net income reaching $73.4 million. The community bank, leveraging its deep roots in Upstate New York, is positioning for further growth in 2026, buoyed by major local investments like Micron's semiconductor project.
CLEAR Secure, the biometric identity company known for its airport expedited lanes, is deepening its ties to core government systems. CEO Caryn Seidman Becker's appointment to the Federal Reserve Bank of New York's board and a new contract with the Centers for Medicare & Medicaid Services signal a strategic push into financial and public health infrastructure.
A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.
Accent Group's strategic partnership with UK retail giant Frasers, including a planned rollout of Sports Direct stores in Australia, is drawing investor focus as it promises to reshape the footwear retailer's earnings profile. The move comes amid volatile share price performance, raising questions about the company's current valuation.
Nutrien Ltd. (TSX:NTR) shares have climbed over 31% in the past year, prompting investors to question if the agricultural giant still presents a buying opportunity. A deep dive into valuation metrics suggests the stock may be fairly priced, but diverging narratives on future growth leave room for debate.
Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.
Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.
As equity markets show signs of fatigue after a prolonged bull run, defensive sectors like utilities are gaining attention. The Vanguard Utilities ETF (VPU), with its low cost and stable dividend yield, presents a compelling option for investors seeking to buffer their portfolios against potential volatility.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Investment firm Giverny Capital Asset Management detailed its sale of Fiserv shares in its 2025 year-end letter, pointing to market fixation on artificial intelligence and the financial technology giant's steep decline. The move highlights a broader divergence between fundamental performance and current investor sentiment.
Investment firm Giverny Capital has sold its entire position in used-car retailer CarMax, a holding of several years, as detailed in its Q4 2025 investor letter. The move highlights a strategic pivot away from traditional retail plays towards perceived higher-growth opportunities in technology, even as the firm's portfolio underperformed major indices last quarter.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Investment firm Giverny Capital Asset Management has sold its position in Align Technology (ALGN), revealing a strategic pivot towards AI-focused equities amid a challenging year where its portfolio lagged the broader market.
While homeownership is a common goal, the investment strategies of the affluent reveal a more nuanced picture. Analysis of wealth tiers shows real estate plays a varying, and often shrinking, role as net worth climbs into the millions.
